Corticosteroids or ACTH for acute exacerbations in multiple sclerosis

Cochrane Database of Systematic Reviews

Volumn 2000, Issue 4, 2000, Pages

  Citterio, Antonietta ^a   La Mantia, Loredana ^b,c   Ciucci, Gabriele ^d   Candelise, Livia ^e   Brusaferri, Fabio ^f   Midgard, Rune ^g,h   Filippini, Graziella ⁱ  

^a C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^b IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

^d SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f MAGGIORE HOSPITAL   (Italy)

^g Molde Hospital HNR   (Norway)

^h NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

ⁱ DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; METHYLPREDNISOLONE; PLACEBO; ANTIINFLAMMATORY AGENT; GLUCOCORTICOID;

DISEASE ACTIVITY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; EVIDENCE BASED MEDICINE; FOLLOW UP; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT DURATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ADRENOCORTICOTROPIC HORMONE; ANTI-INFLAMMATORY AGENTS; GLUCOCORTICOIDS; HUMANS; METHYLPREDNISOLONE; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIALS;

EID: 0034564557     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD001331     Document Type: Review

References (84)

1. Durelli L, Baggio GF, Bergamasco B, Barile C, Cocito D, Delsedime M, et al. Early immunosuppressive effect of parenteral methylprednisolone in the treatment of multiple sclerosis. Acta Neurologica 1985;7(3-4):338-44. [MEDLINE: 86047230]
2. Durelli L, Cocito D, Riccio A, Barile C, Bergamasco B, Baggio GF, et al. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations. Neurology 1986;36(2):238-43. [MEDLINE: 86119115]
3. Filipovic SR, Drulovic J, Stojsavljevic N, Levic Z. The effects of high-dose intravenous methylprednisolone on event-related potentials in patients with multiple sclerosis. Journal of the Neurological Sciences 1997;152(2):147-53. [MEDLINE: 98076017;: EMBASE-1997368770]
4. Miller H, Newell DJ, Ridley A. Treatment of acute exacerbations with corticotrophin (A.C.T.H.). Lancet 1961;2:1120-2.
5. Milligan NM, Newcombe R, Compston DAS. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1 Clinical effects. Journal of Neurology, Neurosurgery & Psychiatry 1987;50(5):511-6. [MEDLINE: 87224999]
6. Rose AS, Kuzma JW, Kurtzke JF, Namerow NS, Sibley WA, Tourtellotte WW. Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo. Final report. Neurology 1970;20(5 Part 2):1-59. [MEDLINE: 70164172]
7. Rose AS, Kuzma JW, Kurtzke JF, Sibley WA, Tourtellotte WW. Cooperative study in the evaluation of therapy in multiple sclerosis; ACTH vs. placebo in acute exacerbations. Preliminary report. Neurology 1968;18(Suppl 6):1-10. [MEDLINE: 68357530]
8. Sellebjerg F, Frederiksen JL, Nielsen PM, Olesen J. Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology 1998;51(2):529-34. [MEDLINE: 98373804;: EMBASE-1998298663]
9. Sellebjerg F, Frederiksen JL, Nielsen PM, Olesen J. Randomized controlled trial of high-dose peroral methylprednisolone in attacks of multiple sclerosis. Ugeskrift for Laeger 1999;161(48):6625-9.
10. Sellebjerg F, Jensen CV, Larsson HB, Frederiksen JL. Gadolinium-enhanced magnetic resonance imaging predicts response to methylprednisolone in multiple sclerosis. Multiple Sclerosis 2003;9(1):102-7.
11. Barkhof F, Hommes OR, Scheltens P, Valk J. Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis. Neurology 1991;41(8):1219-22.
12. Beretta S, Checcarelli N, Manfredi L, Adobbati L, Garavaglia P, Guidotti M, et al.[Efficacia del trattamento con ripetute megadosi di metilprednisolone nella profilassi delle ricadute nella sclerosi multipla tipo relapsing-remitting]. XXXVII Congresso Nazionale della Società dei Neurologi Neurochirurghi e Neuroradiologi Ospedalieri S.N.O. Como, 1997:37-8.
13. Boman K, Hokkanen E, Jarho L, Kivalo E. Double-blind study of the effect of corticotropin treatment in multiple sclerosis. Annales Medicinae Internae Fenniae 1966;55(3):71-3. [MEDLINE: 67165123]
14. Buckley C, Kennard C, Swash M. Treatment of acute exacerbations of multiple sclerosis with intravenous methyl-prednisolone. Journal of Neurology, Neurosurgery and Psychiatry 1982;45(2):179-80.
15. Burnham JA, Wright RR, Dreisbach J, Murray RS. The effect of high-dose steroids on MRI gadolinium enhancement in acute demyelinating lesions. Neurology 1991;41(9):1349-54.
16. Ciccone A, Beretta S, Pellegrini G, BPSM (Boli Steroidei Preventivi nella Sclerosi Multipla) Group. Periodic intravenous methylprednisolone megadoses to prevent relapses in multiple sclerosis. Data on file.
17. Compston DAS, Milligan NM, Hughes PJ, Gibbs J, McBroom V, Morgan BP, et al. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 2. laboratory results. Journal of Neurology, Neurosurgery and Psychiatry 1987;50(5):517-22. [MEDLINE: 87224999]
18. Dong Y, Li LL, Li YX. Clinical application of different protocols of glucocorticoids on treating multiple sclerosis. Journal of Clinical Neurology 2012;25:144-6.
19. Dowling PC, Bosch VV, Cook SD. Possible beneficial effect of high-dose intravenous steroid therapy in acute demyelinating disease and transverse myelitis. Neurology 1980;30(7):33-6.
20. Frequin ST, Wevers RA, Braam M, Barkhof F, Hommes OR. Decreased vitamin B12 and folate levels in cerebrospinal fluid and serum of multiple sclerosis patients after high-dose intravenous methylprednisolone. Journal of Neurology 1993;240(5):305-8.
21. Frequin ST, Lamers KJ, Barkhof F, Borm GF, Hommes OR. Follow-up study of MS patients treated with high-dose intravenous methylprednisolone. Acta Neurologica Scandinavica 1994;90(2):105-10.
22. Goodkin DE, Kinkel RP, Weinstock-Guttman B, VanderBrug-Medendorp S, Secic M, Gogol D, et al. A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis. Neurology 1998;51(1):239-45.
23. Gunal D, Tekin S, Tanridag T, Aktan S. The effect of methylprednisolone on the disease progression in multiple sclerosis. European Journal of Neurology 1996;3:59.
24. Hoogervorst EL, Polman CH, Barkhof F. Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone. Multiple Sclerosis 2002;8(5):415-9.
25. Hoogstraten MC, Minderhoud JM. Long-term effect of ACTH treatment of relapse in multiple sclerosis. Acta Neurologica Scandinavica 1990;82(1):74-7. [MEDLINE: 91050360;: EMBASE-1990255121]
26. Kesselring J, Miller DH, MacManus DG, Johnson G, Milligan NM, Scolding N, et al. Quantitative magnetic resonance imaging in multiple sclerosis: the effect of high dose intravenous methylprednisolone. Journal of Neurology, Neurosurgery and Psychiatry 1989;52(1):14-7.
27. Kiessling, W. Transdermal effects of a synthetic alpha-melanotropin/corticotropin analog in multiple sclerosis. Archives of Neurology 1987;44:995.
28. Kupersmith MJ, Kaufman D, Paty DW, Ebers G, McFarland H, Johnson K, et al. Megadose corticosteroids in multiple sclerosis. Neurology 1994;44(1):1-4.
29. Marforio S. ACTH 1-17 effects in multiple sclerosis. La Ricerca in Clinica e in Laboratorio 1984;14(2):253-5. [MEDLINE: 85016360]
30. Martin E, Kirker J. A controlled trial of ACTH in multiple sclerosis. Journal of the Irish Medical Association 1964;54:146-49.
31. Martinez-Caceres EM, Barrau MA, Brieva L, Espejo C, Barbera N, Montalban X. Treatment with methylprednisolone in relapses of multiple sclerosis patients: immunological evidence of immediate and short-term but not long-lasting effects. Clinical and Experimental Immunology 2002;127(1):165-71.
32. Merrit HH, Glaser GH, Herrmann C. A study of the short- and long-term effects of adrenal steroids on the clinical patterns of multiple sclerosis. Annals New York Academy of Sciences 1954;58:625-32.
33. Millar JHD, Vas CJ, Noronha MJ, Liversedge LA, Rawson MD. Long-term treatment of multiple sclerosis with corticotrophin. The Lancet 1967;2(7513):429-31. [MEDLINE: 67201180]
34. Miller H, Newell DJ, Ridley A. Trials of maintenance treatment with prednisolone and soluble aspirin. The Lancet 1961;1:127-9.
35. Miller DH, Thompson AJ, Morrissey SP, MacManus DG, Moore SG, Kendall BE, et al. High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. Journal of Neurology, Neurosurgery and Psychiatry 1992;55(6):450-3.
36. Newman PK, Saunders M, Tilley PJ. Methylprednisolone therapy in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry 1982;45(10):941-2.
37. Repovic P, Lublin FD. Treatment of multiple sclerosis exacerbations. Neurologic Clinics 2011;29(2):389-400.
38. Rinne UK, Sonninen V, Tuovinen T. Corticotrophin treatment in multiple sclerosis. Acta Neurologica Scandinavica 1968;44(2):207-18. [MEDLINE: 69029869]
39. Rumbach L, Dietemann JL, Tranchant C, Bodiguel E, Warter JM, Collard M. Magnetic resonance imaging after a one-month interval of lesions of multiple sclerosis in 2 populations, one during an acute attack treated with methylprednisolone, the other stable with no treatment. Revue Neurologique 1990;146(6-7):430-3.
40. Schweingruber A, Reichardt SD, Reichardt HM. Mechanisms of glucocorticoids in control of neuroinflammation. Journal of Neuroendocrinology 2011;24:174-82.
41. Sellebjerg F, Nielsen HS, Frederiksen JL, Olesen J. A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology 1999;52(7):1479-84.
42. Then Bergh F, Kumpfel T, Grasser A, Rupprecht R, Holsboer F, Trenkwalder C. Combined treatment with corticosteroids and moclobemide favours normalization of hypothalamo-pituitary-adrenal axis dysregulation in relapsing-remitting multiple sclerosis: a randomized, double blind trial. The Journal of Clinical Endocrinology and Metabolism 2001;86(4):1610-5.
43. Tourtellotte WW, Haerer AF, Arbor A. Use of an oral corticosteroid in the treatment of multiple sclerosis. A double-blind study. Archives of Neurology 1965;12:536-45.
44. Tourtellotte WW, Baumhefner RW, Potvin AR, Ma BI, Potvin JH, Mendez M, et al. Multiple sclerosis de novo CNS IgG synthesis: effect of ACTH and corticosteroids. Neurology 1980;30(11):1155-62.
45. Trotter JL, Garvey WF. Prolonged effects of large-dose methylprednisolone infusion in multiple sclerosis. Neurology 1980;30(7):702-8.
46. Versino M, Bergamaschi R, Callieco R, Romani A, Castelnovo G, Beltrami G, et al. Eye movement quantitative evaluation before and after high-dose 6-methylprednisolone in multiple sclerosis. Acta Neurologica Scandinavica 1994;89(2):105-10.
47. Visser LH, Beekman R, Tijssen CC, Uitdehaag BM, Lee ML, Movig KL, et al. A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS. Multiple Sclerosis 2004;10(1):89-91.
48. Whitaker JN, Layton BA, Herman PK, Kachelhofer RD, Burgard S, Bartolucci AA. Correlation of myelin basic protein-like material in cerebrospinal fluid of multiple sclerosis patients with their response to glucocorticoid treatment. Annals of Neurology 1993;33(1):10-7.
49. Zivadinov R, Rudick RA, De Masi R, Nasuelli D, Ukmar M, Pozzi-Mucelli RS, et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001;57(7):1239-47.
50. Atalay K, Diren HB, Gelmez S, Incesu L, Terzi M. The effectiveness of magnetization transfer technique in the evaluation of acute plaques in the central nervous system of multiple sclerosis patients and its correlation with the clinical findings. Diagnostic and Interventional Radiology 2005;11(3):137-41.
51. Barkhof R, Frequin ST, Hommes OR, Lamers K, Scheltens Ph, van Geel WJ, et al. A correlative triad of gadolinium-DTPA MRI, EDSS, and CSF-MBP in relapsing multiple sclerosis patients treated with high-dose intravenous methylprednisolone. Neurology 1992;42:63-7.
52. Barnes D, Hughes RA, Morris RW, Wade-Jones O, Brown P, Britton T, et al. Randomised trial of oral and intravenous methylprednisolone in acute relapses in multiple sclerosis. Lancet 1997;349(9056):902-6. [MEDLINE: 97247116;: EMBASE-1997097394]
53. Brooks M. ACTH pulse therapy may benefit breakthrough MS. American Academy of Neurology (AAN) 65th Annual Meeting; March 16-23; San Diego, California. 2013; Vol. Abstract P04.269.
54. Burton JM, O'Connor PW, Hohol M, Beyene J. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.CD006921]
55. Ciccone A, Beretta S, Brusaferri F, Galea I, Protti A, Spreafico C. Corticosteroids for the long-term treatment in multiple sclerosis. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD006264]
56. Compston A. The genetic epidemiology of multiple sclerosis [Review]. Philosophical Transactions of the Royal Society of London - Series B: Biological Sciences 1999;354(1390):1623-34. [MEDLINE: 20071270]
57. Anderson B, ChairDiem-Kieu H. Peripheral and central nervous system drugs advisory committee UCM215396, 2010. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/peripheralandcentralnervoussystemdrugsadvisorycommittee/ucm215396.pdf (accessed 31 March 2013).
58. Gal RL, Vedula SS, Beck R. Corticosteroids for treating optic neuritis. Cochrane Database of Systematic Reviews 2012, Issue 4. [DOI: 10.1002/14651858.CD001430]
59. Glaser GH, Merritt HH. Effect of ACTH and cortisone in multiple sclerosis. Transactions of the American Neurological Association 1951;56:130-3.
60. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
61. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33(11):1444-52. [MEDLINE: 84040263]
62. Levine T. Treating refractory dermatomyositis or polymyositis with adrenocorticotropin hormone gel: a retrospective case series. Drug Design Development and Therapy 2012;6:133-9.
63. Lindquist S, Hassinger S, Lindquist JA, Sailer M. The balance of pro-inflammatory and trophic factors in multiple sclerosis patients: effects of acute relapse and immunomodulatory treatment. Multiple Sclerosis 2011;17(7):851-66.
64. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA). Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46(4):907-11. [MEDLINE: 96373770;: EMBASE-1996125709]
65. Martinelli V, Rocca MA, Annovazzi P, Pulizzi A, Rodegher M, Martinelli Boneschi F, et al. A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS. Neurology 2009;73(22):1842-8.
66. Martínez-Cáceres EM, Barrau MA, Brieva L, Espejo C, Barberà N, Montalban X. Treatment with methylprednisolone in relapses of multiple sclerosis patients: immunological evidence of immediate and short-term but not long-lasting effects. Clinical and Experimental Immunology 2002;127(1):165-71.
67. McDonald WI, Halliday AM. Diagnosis and classification of multiple sclerosis. British Medical Bullettin 1977;33(1):4-9. [MEDLINE: 77088528]
68. McEwen BS, Biron CA, Brunson KW, Bulloch K, Chambers WH, Dhabhar FS, et al. The role of adrenocorticoids as modulators of immune function in health and disease: neural endocrine and immune interactions. Brain Research. Brain Research Reviews 1997;23(1-2):79-133. [MEDLINE: 97217627;: EMBASE-1997063673]
69. Meyers LW. Treatment of multiple sclerosis with ACTH and corticosteroids. In: Rudick RA, Goodkin DE editor(s). Treatment of Multiple Sclerosis. Trial Design, Results and Future Perspectives. 1st Edition. London: Springer Verlag, 1992:135-56.
70. Morrow SA, Metz LM, Kremenchutzky M. High dose oral steroids commonly used to treat relapses in Canadian MS clinics. Canadian Journal of Neurological Sciences 2009;36(2):213-5.
71. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Annals of Neurology 1983;13(3):227-31. [MEDLINE: 83202737]
72. Pugliatti M, Sotgiu S, Rosati G. The worldwide prevalence of multiple sclerosis. Clinical Neurology and Neurosurgery 2002;104:182-91.
73. Rentzos M, Nikolaou C, Rombos A, Evangelopoulos ME, Kararizou E, Koutsis G, et al. Effect of treatment with methylprednisolone on the serum levels of IL-12, IL-10 and CCL2 chemokine in patients with multiple sclerosis in relapse. Clinical Neurology and Neurosurgery 2008;110(10):992-6.
74. Repovic P, Lublin FD. Treatment of multiple sclerosis exacerbations. Neurologic Clinics 2011;29:369-400.
75. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2013.
76. Sapolsky RM, Romero LM, Munck AU. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocrine Reviews 2000;21(1):55-89. [MEDLINE: 20161560]
77. Schimmer BP, Parker KL. ACTH, adrenocortical steroids and their synthetic analogs. In: Hardman JG, Limbird LE editor(s). Goodman & Gilman's The Pharmacologic Basis of Therapeutics. New York: McGraw Hill, 2001:1649-77.
78. Sellebjerg F, Barnes D, Filippini G, Midgard R, Montalban X, Rieckmann P, et al. EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. European Journal of Neurology 2005;12:939-46.
79. Sellebjerg F, Jensen CV, Larsson HB, Frederiksen JL. Gadolinium-enhanced magnetic resonance imaging predicts response to methylprednisolone in multiple sclerosis. Multiple Sclerosis 2003;9(1):102-7.
80. Thompson AJ, Kennard C, Swash M, Summers B, Yuill GM, Shepherd DI, et al. Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS. Neurology 1989;39(7):969-71. [MEDLINE: 89295951;: EMBASE-1989170466]
81. Tremlett HL, Luscombe DK, Wiles CM. Use of corticosteroids in multiple sclerosis by consultant neurologists in the United Kingdom. Journal of Neurology, Neurosurgery and Psychiatry 1998;65(3):362-5. [MEDLINE: 98397167;: EMBASE-1998300103]
82. World Health Organization (WHO) and Multiple Sclerosis International Federation. Atlas: Multiple Sclerosis Resources in the World 2008. http://www.who.int/mental_health/neurology/Atlas_MS_WEB.pdf (accessed 31 March 2013). [ISBN 978 92 4 156375 8]
83. Willer CJ, Ebers GC. Susceptibility to multiple sclerosis: interplay between genes and environment. Current Opinion in Neurology 2000;13(3):241-7.
84. Filippini G, Brusaferri F, Sibley WA, Citterio A, Ciucci G, Midgard R, et al. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database of Systematic Reviews 2000, Issue 4. [DOI: 10.1002/14651858.CD001331]